LON:ETX

e-therapeutics Share Forecast, Price & News

GBX 19.52
-0.43 (-2.16 %)
(As of 04/14/2021 03:09 PM ET)
Add
Compare
Today's Range
19
Now: GBX 19.52
20.94
50-Day Range
20.16
MA: GBX 22.85
25.15
52-Week Range
10.60
Now: GBX 19.52
26.80
Volume67,672 shs
Average Volume935,220 shs
Market Capitalization£82.14 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
e-Therapeutics plc engages in the discovery of drugs through its proprietary network-driven drug discovery platform in the United Kingdom. It is developing two NDD-derived immuno-oncology programs, including tryptophan catabolism and immune checkpoint modulation. The company, through its subsidiary, Searchbolt Limited, develops search engine technology. The company has collaborations with C4X Holdings PLC, Intellegens, Biorelate, Novo Nordisk, and Galapagos NV. e-Therapeutics plc was founded in 2001 and is based in Long Hanborough, the United Kingdom.

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+44-1993-880000
Employees16
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales£305,000.00
Cash FlowGBX 3.43 per share
Book ValueGBX 3.70 per share

Profitability

Miscellaneous

Market Cap£82.14 million
Next Earnings DateN/A
OptionableNot Optionable

Headlines

Are Insiders Buying e-therapeutics plc (LON:ETX) Stock?
January 2, 2021 |  finance.yahoo.com
E-Therapeutics hits 52w high – but will it continue?
April 28, 2020 |  uk.finance.yahoo.com
E-therapeutics Regulatory News
February 18, 2020 |  www.lse.co.uk
e-Therapeutics PLC
October 24, 2019 |  www.barrons.com
E-therapeutics Share Price (ETX)
October 7, 2019 |  www.lse.co.uk
e-therapeutics to work with top pharma company
August 13, 2019 |  markets.ft.com
E-therapeutics Share Chat
March 20, 2019 |  www.lse.co.uk
See More Headlines

MarketRank

Overall MarketRank

0.42 out of 5 stars

Analyst Opinion: 0.0Community Rank: 2.1Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
GBX 19.52
-0.43 (-2.16 %)
(As of 04/14/2021 03:09 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ETX News and Ratings via Email

Sign-up to receive the latest news and ratings for ETX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











e-therapeutics (LON:ETX) Frequently Asked Questions

What stocks does MarketBeat like better than e-therapeutics?

Wall Street analysts have given e-therapeutics a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but e-therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

How were e-therapeutics' earnings last quarter?

e-therapeutics plc (LON:ETX) released its earnings results on Tuesday, March, 17th. The company reported ($0.87) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.90) by $0.03.
View e-therapeutics' earnings history
.

How has e-therapeutics' stock price been impacted by Coronavirus?

e-therapeutics' stock was trading at GBX 8.10 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, ETX shares have increased by 141.0% and is now trading at GBX 19.52.
View which stocks have been most impacted by COVID-19
.

Who are e-therapeutics' key executives?

e-therapeutics' management team includes the following people:
  • Mr. Ahmad Ali Mortazavi, CEO & Director (Age 50)
  • Dr. Karl Keegan BSc, MPhil, Ph.D., MSc, Chief Financial Officer (Age 54)
  • Mr. Jonny Wray, Chief Technology Officer
  • Mr. Alan Whitmore, Chief Scientific Officer
  • Ms. Sarah Clare, Director of Fin. & Compliance
  • Ms. Stephanie Maley, Chief People Officer
  • Mr. Colin Stubberfield, Chief Research Officer
  • Dr. Laura Roca-Alonso, Chief Bus. Officer
  • Adam Sardar, Head of Data Science
  • Ms. Nadine Fairhurst-Groethe, Financial Controller

Who are some of e-therapeutics' key competitors?

What other stocks do shareholders of e-therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other e-therapeutics investors own include Radware (RDWR), Sound Energy (SOU), 4D pharma (DDDD), Chicken Soup for the Soul Entertainment (CSSE), Crescent Point Energy (CPG), Collagen Solutions plc (COS.L) (COS), (BV), BP (BP), Bushveld Minerals (BMN) and Alstom (ALSMY).

What is e-therapeutics' stock symbol?

e-therapeutics trades on the London Stock Exchange (LON) under the ticker symbol "ETX."

How do I buy shares of e-therapeutics?

Shares of ETX and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What is e-therapeutics' stock price today?

One share of ETX stock can currently be purchased for approximately GBX 19.52.

How much money does e-therapeutics make?

e-therapeutics has a market capitalization of £82.14 million and generates £305,000.00 in revenue each year.

How many employees does e-therapeutics have?

e-therapeutics employs 16 workers across the globe.

What is e-therapeutics' official website?

The official website for e-therapeutics is www.etherapeutics.co.uk.

Where are e-therapeutics' headquarters?

e-therapeutics is headquartered at 17 Blenheim Office Park, WITNEY, OX29 8LN, United Kingdom.

How can I contact e-therapeutics?

e-therapeutics' mailing address is 17 Blenheim Office Park, WITNEY, OX29 8LN, United Kingdom. The company can be reached via phone at +44-1993-880000.


This page was last updated on 4/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.